-
Notifications
You must be signed in to change notification settings - Fork 0
/
Copy pathmab-description.yml
181 lines (164 loc) · 10.4 KB
/
mab-description.yml
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
mab-desc_Bamlanivimab: |-
**Bamlanivimab** (aka LY-CoV555; LY3819253) is an ACE2-competing mAb that
binds RBD in the up and down configurations. It reduces upper airway and
lower airway virus levels in rhesus macaques. It has been shown to reduce
virus levels and possibly hospitalizations in a phase II trial. A phase III
trial in hospitalized patients was discontinued because of lack of efficacy.
It is also being studied in combination with Etesevimab which appears to be
the same mAb as LY-CoV016, CB6 and JS016. Bamlanivimab received FDA emergence
use authorization (EUA) on November 9, 2020. The EUA was revoked on April 19,
2021, although the combination EUA of Bamlanivimab+Etesevimab is still
available.
Bamlanivimab is developed by AbCellera Biologics and Eli Lilly.
mab-desc_Etesevimab: |-
**Etesevimab** (aka CB6; JS016; LY-CoV016; LY3832479) is an ACE2-competing
neutralizing mAb derived from SARS-CoV-2 convalescent memory B cells. It has
been shown to reduice virus levels and lung pathology when administered 1 day
before or after infection of rhesus macaques. Its Fc receptor has been
mutated (LALA) to prolong its half-life. It is being evaluated as monotherapy
in a phase I trial and in combination with Bamlanivimab in a phase II trial.
Etesevimab is developed by Junshi Biosciences and Institute of Microbiology,
Chinese Academy of Science (IMCAS). It is licensed to Eli Lilly.
mab-desc_Bamlanivimab+Etesevimab: |-
**Bamlanivimab and Etesevimab** are administered together via intravenous
infusion as a treatment for COVID-19. The combination is granted an emergence
use authorization (EUA) by the FDA on November 9, 2020.
**Bamlanivimab** (aka LY-CoV555; LY3819253) is an ACE2-competing mAb that
binds RBD in the up and down configurations. It reduces upper airway and
lower airway virus levels in rhesus macaques. It has been shown to reduce
virus levels and possibly hospitalizations in a phase II trial. A phase III
trial in hospitalized patients was discontinued because of lack of efficacy.
It is also being studied in combination with Etesevimab which appears to be
the same mAb as LY-CoV016, CB6 and JS016. Bamlanivimab received FDA emergence
use authorization (EUA) on November 9, 2020. The EUA was revoked on April 19,
2021, although the combination EUA of Bamlanivimab+Etesevimab is still
available. BAM is developed by AbCellera Biologics and Eli Lilly.
**Etesevimab** (aka CB6; JS016; LY-CoV016; LY3832479) is an ACE2-competing
neutralizing mAb derived from SARS-CoV-2 convalescent memory B cells. It has
been shown to reduice virus levels and lung pathology when administered 1 day
before or after infection of rhesus macaques. Its Fc receptor has been
mutated (LALA) to prolong its half-life. It is being evaluated as monotherapy
in a phase I trial and in combination with Bamlanivimab in a phase II trial.
ETE is developed by Junshi Biosciences and Institute of Microbiology, Chinese
Academy of Science (IMCAS). It is licensed to Eli Lilly.
mab-desc_Casirivimab: |-
The REGN panel of neutralizing mAbs was derived primarily from VelocImmune
mice immunized with trimeric spike boosted with RBD. **Casirivimab**
(REGN10933) and Imdevimab (REGN10987) are ACE2-competing mAbs that bind to
non-overlapping RBD epitopes. They have been been shown to elicit ADCC and
ADCP in vitro. This pair of mAbs reduces virus levels and lung pathology in
rhesus macaque treatment and prevention models. The combination has
demonstrated preliminary virological efficacy in a phase II trial of
outpatients. A phase III trial in hospitalized patients was discontinued
because of lack of efficacy. This pair of mAbs is granted an emergence use
authorization (EUA) by the FDA on November 20, 2020.
Casirivimab is developed by Regeneron Pharmaceuticals.
mab-desc_Imdevimab: |-
The REGN panel of neutralizing mAbs was derived primarily from VelocImmune
mice immunized with trimeric spike boosted with RBD. Casirivimab (REGN10933)
and **Imdevimab** (REGN10987) are ACE2-competing mAbs that bind to
non-overlapping RBD epitopes. They have been been shown to elicit ADCC and
ADCP in vitro. This pair of mAbs reduces virus levels and lung pathology in
rhesus macaque treatment and prevention models. The combination has
demonstrated preliminary virological efficacy in a phase II trial of
outpatients. A phase III trial in hospitalized patients was discontinued
because of lack of efficacy. This pair of mAbs is granted an emergence use
authorization (EUA) by the FDA on November 20, 2020.
Imdevimab is developed by Regeneron Pharmaceuticals.
mab-desc_Casirivimab+Imdevimab: |-
The REGN panel of neutralizing mAbs was derived primarily from VelocImmune
mice immunized with trimeric spike boosted with RBD. **Casirivimab**
(REGN10933) **and Imdevimab** (REGN10987) are ACE2-competing mAbs that bind
to non-overlapping RBD epitopes. They have been been shown to elicit ADCC and
ADCP in vitro. This pair of mAbs reduces virus levels and lung pathology in
rhesus macaque treatment and prevention models. The combination has
demonstrated preliminary virological efficacy in a phase II trial of
outpatients. A phase III trial in hospitalized patients was discontinued
because of lack of efficacy. This pair of mAbs is granted an emergence use
authorization (EUA) by the FDA on November 20, 2020.
Casirivimab and Imdevimab are both developed by Regeneron Pharmaceuticals.
mab-desc_Sotrovimab: |-
S309 is derived from SARS-CoV-1 convalescent memory B cells that recognize
SARS-CoV-2 trimeric spike. It is a non-ACE2-competing mAb that binds to the
RBD core region and cross-neutralizes SARS-CoV-1. It binds to RBD in its up
and down configurations and it binds to a unique proteoglycan epitope at
N343. It has been shown to elicit ADCC and ADCP in vitro and it has undergone
Fc modifications to prolong its half-life. **Sotrovimab** (aka VIR-7831,
GSK4182136) is developed based on S309, and is being studied in a phase II
trial. Sotrovimab is granted an emergence use authorization (EUA) by the FDA
on May 26, 2021.
VIR-7831 is developed by VIR Biotechnology and GlaxoSmithKline.
mab-desc_Cilgavimab: |-
**Cilgavimab** (aka AZD1061; COV2-2130) is an ACE2-competing monoclonal
antibody that binds RBD in the up and down configuration. It reduces weight
loss and lung virus levels in a mouse prevention model. Tixagevimab and
Cilgavimab bind to nonoverlapping RBD epitopes. The combination of
Tixagevimab and Cilgavimab (aka AZD7442) is granted an emergence use
authorization (EUA) by the FDA on December 8, 2021.
Cilgavimab is developed by AstraZeneca.
mab-desc_Tixagevimab: |-
**Tixagevimab** (aka AZD8895; COV2-2196) is an ACE2-competing monoclonal
antibody that binds RBD in the up configuration. It reduces weight loss and
lung virus levels in a mouse prevention model. It also reduces lung virus
levels in rhesus macaques. Tixagevimab and Cilgavimab bind to nonoverlapping
RBD epitopes. The combination of Tixagevimab and Cilgavimab (aka AZD7442) is
granted an emergence use authorization (EUA) by the FDA on December 8, 2021.
Tixagevimab is developed by AstraZeneca.
mab-desc_Cilgavimab+Tixagevimab: |-
**Cilgavimab and Tixagevimab** (aka AZD7447) is a comination of two
ACE2-competing monoclonal antibodies that bind RBD in the up and down
configuration. Tixagevimab and Cilgavimab bind to nonoverlapping RBD
epitopes. This combination is granted an emergence use authorization (EUA) by
the FDA on December 8, 2021.
Cilgavimab and Tixagevimab are both developed by AstraZeneca.
mab-desc_C135: |-
**C135** is an ACE2-competing neutralizing monoclonal antibody derived from
SARS-CoV-2 convalescent memory B cells that recognize RBD. It binds to RBD's
up and down configurations. C121 / C135 and C144 / C135 bind to
non-overlapping epitopes.
C135 is developed by The Rockefeller University.
mab-desc_C144: |-
**C144** is an ACE2-competing neutralizing monoclonal antibody derived from
SARS-CoV-2 convalescent memory B cells that recognize RBD. It binds to RBD's
up and down configurations. C144 / C135 bind to non-overlapping epitopes.
C144 uses its CDR(H)3 to bridge two neighboring RBDs and to stabilize spike
in the closed state.
C144 is developed by The Rockefeller University.
mab-desc_Amubarvimab: |-
**Amubarvimab** (aka BRII-196; P2C-1F11) is an investigational, neutralizing
monoclonal antibody developed by Brii Biosciences.
mab-desc_Romlusevimab: |-
**Romlusevimab** (aka BRII-198; P2B-1G5) is an investigational, neutralizing
monoclonal antibody developed by Brii Biosciences.
mab-desc_Amubarvimab+Romlusevimab: |-
**Amubarvimab and Romlusevimab** are non-competing SARS-CoV-2 monoclonal
neutralizing antibodies derived from convalesced COVID-19 patients. The
combination is approved by the China National Medical Products Administration
(NMPA).
AMU and ROM are developed by Brii Biosciences.
mab-desc_Regdanvimab: |-
**Regdanvimab** (aka Regkirona; CT-P59) is a human monoclonal antibody used
for the treatment of COVID-19. The antibody is directed against the spike
protein of SARS-CoV-2. It is developed by Celltrion. The medicine is given by
infusion (drip) into a vein. Regdanvimab was approved for medical use in the
European Union in November 2021.
mab-desc_Adintrevimab: |-
**Adintrevimab** (aka ADG20; ADG-2) is an ACE2-competing neutralizing
monoclonal antibody that binds to an epitope located in between the class 1
and class 4 sites. It is developed by Adagio Therapeutics. It is being
studied in phase II and III clinical trials.
mab-desc_Bebtelovimab: |-
**Bebtelovimab** (aka LY-CoV1404; LY3853113) is an ACE2-competing
neutralizing monoclonal antibody binds to RBD. It is derived from a
convalescent COVID-19 patient sample. It was granted an emergency use
authorization (EUA) by the FDA in February 2022.
Bebtelovimab is developed by Eli Lilly.
mab-desc_Vir-7832: |-
**Vir-7832** is an investigational dual-action SARS-CoV-2 monoclonal antibody
that binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1. entry
into healthy cells and an enhanced ability to clear infected cells. It is
being studied in a phase 1b/2a clinical trial.
Vir-7832 is developed by VIR Biotechnology and GlaxoSmithKline.
mab-desc_DXP-604: |-
**DXP-604** is an investigational monoclonal antibody developed by BeiGene
and Singlomics. Is is undergoing a phase I clinical trial.